Filing Details

Accession Number:
0001209191-19-053739
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-10-21 19:31:46
Reporting Period:
2019-10-17
Accepted Time:
2019-10-21 19:31:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1131324 Genomic Health Inc GHDX Services-Medical Laboratories (8071) 770552594
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1649191 Laura Leber 301 Penobscot Dr.
Redwood City CA 94063
Chief Communication Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-03-11 275 $0.00 13,420 No 5 G Direct
Common Stock Acquisiton 2019-10-17 13,183 $22.98 26,919 No 4 M Direct
Common Stock Disposition 2019-10-17 13,183 $70.94 13,736 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 5 G Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2019-10-17 13,183 $0.00 13,183 $22.98
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2021-01-27 No 4 M Direct
Footnotes
  1. Includes an aggregate of 9,384 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
  2. These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on November 14, 2018.
  3. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
  4. Represents weighted average sale price. Actual sale prices ranged from $70.71 to $71.135.
  5. The option became exercisable as to 25% of the shares on January 27, 2012, and became exercisable as to 1/48th of the shares each full month thereafter.